Sherman Prize Announces 2017 Award Recipients

David T. Rubin, MD, FACG Sherman Prize, Inspiring Excellence in Crohn’s and Colitis, Announces 2017 Award Recipients By David T. Rubin, MD, FACG, ACG Board of Trustees, University of Chicago Medicine The winners of the second annual Sherman ...

Dr. Rubin on the Second Annual Sherman Prize for Excellence in Crohn’s and Colitis

David T. Rubin, MD, FACG Recognizing Exceptional and Pioneering Contributions in Crohn’s Disease and Ulcerative Colitis New Deadline: May 15 By David T. Rubin, MD, FACG, ACG Board of Trustees, Chair, Sherman Prize Selection Committee, University ...

Sherman Prize Honors Excellence in IBD

Sherman Prize Honors Excellence in Crohn’s and Colitis by Sunanda V. Kane, MD, FACG This week, the recipients of the inaugural Sherman Prize were announced. As a member of the Prize Selection Committee, I am proud to share this news with ...

“Enter the Biosimilars”: An ACG-CCFA Webinar with Dr. David T. Rubin

ACG and CCFA Co-Hosted an IBD Circle Webinar Optimizing Medical Therapy in IBD: Enter the Biosimilars June 29, 2016 David T. Rubin, MD, FACG You can listen this webinar with David T. Rubin, MD, FACG who shares insights on how clinicians ...

A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study

  Stephen B. Hanauer, MD, FACG Oral 19 A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study Author ...

Now Available: New ACG Ulcerative Colitis Guidebook & Video for Your Patients

A new guidebook and video is now available from the American College of Gastroenterology to help patients understand that ulcerative colitis (UC) is a treatable condition that can be managed effectively. This valuable resource is designed for ...